MX2021003002A - Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo. - Google Patents

Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo.

Info

Publication number
MX2021003002A
MX2021003002A MX2021003002A MX2021003002A MX2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A MX 2021003002 A MX2021003002 A MX 2021003002A
Authority
MX
Mexico
Prior art keywords
composition
fibrotic diseases
active ingredient
treating fibrotic
thioacetamide compound
Prior art date
Application number
MX2021003002A
Other languages
English (en)
Inventor
Suk Hyo Suh
Seong Jin Kim
Original Assignee
Cellionbiomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellionbiomed Inc filed Critical Cellionbiomed Inc
Publication of MX2021003002A publication Critical patent/MX2021003002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición para el tratamiento de enfermedades fibróticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo, y más específicamente a una composición para el tratamiento de enfermedades fibróticas, que suprime la expresión de la proteína del canal KCa2.3 en una membrana celular y tiene excelentes efectos de tratamiento particularmente sobre la fibrosis hepática y la fibrosis pulmonar.
MX2021003002A 2018-09-14 2019-09-11 Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo. MX2021003002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180110442A KR102126389B1 (ko) 2018-09-14 2018-09-14 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
PCT/KR2019/011834 WO2020055166A1 (ko) 2018-09-14 2019-09-11 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2021003002A true MX2021003002A (es) 2021-05-27

Family

ID=69777998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003002A MX2021003002A (es) 2018-09-14 2019-09-11 Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo.

Country Status (11)

Country Link
US (1) US20210260018A1 (es)
EP (1) EP3851099A4 (es)
JP (1) JP7184241B2 (es)
KR (1) KR102126389B1 (es)
CN (1) CN113038942A (es)
AU (1) AU2019338896B2 (es)
BR (1) BR112021004766A2 (es)
CA (1) CA3112695C (es)
MX (1) MX2021003002A (es)
RU (1) RU2769364C1 (es)
WO (1) WO2020055166A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102277739B1 (ko) * 2019-12-11 2021-07-15 셀라이온바이오메드 주식회사 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물
JP2024528979A (ja) 2021-08-02 2024-08-01 セルリオンバイオメッド インク． ベンズヒドリルチオアセトアミド化合物を有効成分として含む肥厚性瘢痕およびケロイド治療用組成物
KR20230019795A (ko) 2021-08-02 2023-02-09 셀라이온바이오메드 주식회사 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 비후성 반흔 및 켈로이드 치료용 조성물
CN113750089B (zh) * 2021-10-13 2023-09-19 南方医科大学南方医院 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520812A (en) 1975-10-02 1978-08-09 Lafon Labor Benzhydrylsulphinyl derivatives
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2528038B2 (fr) * 1982-06-04 1985-08-09 Lafon Labor Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2606015B1 (fr) * 1986-08-13 1989-05-19 Lafon Labor Derives du benzhydrylthiomethane, leurs procedes de preparation et leurs applications en therapeutique
FR2708201B1 (fr) * 1993-06-30 1995-10-20 Lafon Labor Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
CA2280309C (en) 1999-08-13 2007-05-08 William Norton Milgram Use of adrafinil to treat behavioral problems in aged canines
WO2005077894A1 (en) * 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
US6870361B2 (en) 2002-12-21 2005-03-22 Agilent Technologies, Inc. System with nano-scale conductor and nano-opening
JP4804922B2 (ja) 2003-08-12 2011-11-02 三井化学株式会社 光硬化型樹脂組成物及びそれを用いたフラットパネルディスプレイ用シール剤
FR2970711B1 (fr) * 2011-01-20 2016-03-04 Hopitaux Paris Assist Publique La lauflumide et ses enantiomeres, preparation et utilisations therapeutiques
KR101414831B1 (ko) * 2011-10-25 2014-07-04 이화여자대학교 산학협력단 모다피닐 또는 이의 유도체를 포함하는 ＫＣａ3.1 채널 매개 질환 치료용 조성물
KR101345860B1 (ko) 2011-10-25 2013-12-30 이화여자대학교 산학협력단 모다피닐 또는 이의 유도체를 포함하는 혈관질환 치료용 조성물
KR101402969B1 (ko) * 2012-01-04 2014-06-03 이화여자대학교 산학협력단 신규한 모다피닐 유도체 및 이를 포함하는 염증 예방 또는 치료용 약학적 조성물
AU2014225550C1 (en) * 2013-03-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
ES2566430B1 (es) * 2014-09-12 2017-01-26 Instituto Aragones De Ciencias De La Salud Esteres de di-benzoato y su uso terapéutico como moduladores negativos de canales de potasio KCa2/3

Also Published As

Publication number Publication date
WO2020055166A1 (ko) 2020-03-19
JP7184241B2 (ja) 2022-12-06
US20210260018A1 (en) 2021-08-26
CN113038942A (zh) 2021-06-25
BR112021004766A2 (pt) 2021-08-31
KR102126389B1 (ko) 2020-06-25
EP3851099A1 (en) 2021-07-21
AU2019338896B2 (en) 2022-10-20
JP2021536459A (ja) 2021-12-27
KR20200031436A (ko) 2020-03-24
RU2769364C1 (ru) 2022-03-30
AU2019338896A1 (en) 2021-04-08
CA3112695A1 (en) 2020-03-19
EP3851099A4 (en) 2023-03-08
CA3112695C (en) 2023-10-10

Similar Documents

Publication Publication Date Title
MX2021003002A (es) Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2020008494A (es) Nanomateriales de silicio-carbono, metodo de su elaboracion y usos.
NZ742208A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
MX2020001403A (es) Nuevos derivados de quinolina.
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
WO2020171727A3 (en) Mucoadhesive compositions and uses thereof
MX2019002396A (es) Composiciones oftalmicas.
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2020011873A (es) Nuevos derivados de quinolina.
EP3760195A4 (en) COMPOSITION WITH 2,3-BUTANEDIOL AS THE ACTIVE SUBSTANCE
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2020001807A (es) Composicion antimicrobiana de limpieza.
EP3760626A4 (en) NEW COMPOUND AND COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS, INCLUDING IT AS AN ACTIVE SUBSTANCE
CR20220112A (es) Composiciones que comprenden tigolaner para el control de parásitos
AU2018259094A1 (en) Heteroarylphenylaminoquinolines and analogues
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
ZA202105026B (en) Insecticidal formulation for vector and pest control with increased contact efficacy
MX2023014776A (es) Sales de sulcardina.
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
ZA202103326B (en) Dentifrice containing sodium bicarbonate and stannous fluoride
WO2018035459A8 (en) Pharmaceutical composition and methods of uses
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.